Entellus Medical, Inc. (NASDAQ:ENTL) VP Kevin L. Mensink sold 10,000 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $18.29, for a total value of $182,900.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Kevin L. Mensink also recently made the following trade(s):
- On Friday, October 20th, Kevin L. Mensink sold 2,500 shares of Entellus Medical stock. The stock was sold at an average price of $19.00, for a total value of $47,500.00.
Shares of Entellus Medical, Inc. (ENTL) traded down 0.29% during midday trading on Friday, hitting $17.48. The stock had a trading volume of 88,092 shares. Entellus Medical, Inc. has a 12-month low of $12.31 and a 12-month high of $20.46. The firm’s market cap is $443.49 million. The company’s 50-day moving average price is $18.33 and its 200-day moving average price is $18.33.
Entellus Medical (NASDAQ:ENTL) last released its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). The business had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. Entellus Medical’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.27) EPS. Equities research analysts forecast that Entellus Medical, Inc. will post ($1.61) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/28/entellus-medical-inc-entl-vp-kevin-l-mensink-sells-10000-shares.html.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors increased its stake in shares of Entellus Medical by 61.7% in the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock worth $114,000 after acquiring an additional 2,635 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock worth $102,000 after acquiring an additional 2,594 shares during the last quarter. First Mercantile Trust Co. increased its stake in shares of Entellus Medical by 45.3% in the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock worth $136,000 after acquiring an additional 2,557 shares during the last quarter. Parametric Portfolio Associates LLC increased its stake in shares of Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock worth $150,000 after acquiring an additional 573 shares during the last quarter. Finally, Kopp Investment Advisors LLC increased its stake in shares of Entellus Medical by 0.5% in the second quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock worth $197,000 after acquiring an additional 55 shares during the last quarter. 70.27% of the stock is currently owned by institutional investors and hedge funds.
Several research firms have weighed in on ENTL. Canaccord Genuity reissued a “hold” rating and set a $17.00 price target on shares of Entellus Medical in a research report on Tuesday, October 17th. BidaskClub downgraded Entellus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Finally, Zacks Investment Research raised Entellus Medical from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $21.86.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.